Innovative Drug Sector Surges Over 20% in Two Months—From "Capital Story" to "Earnings Reality," Upstream Supply Chains Are Becoming Beneficiaries
I. A Shift Worth Watching
If you have been following the innovative drug industry, the changes over the past week are worth noting.
On August 4, A-share innovative drug stocks surged sharply, with multiple stocks including WuXi AppTec, Asymchem, and Luoxin Pharma hitting the daily limit. Since June 9, the CSI Innovative Drug Index has accumulated gains of over 20%. This is not just a one-day rally—it is the result of two months of sustained momentum.
On August 3, WuXi AppTec significantly raised its full-year 2026 guidance: revenue from RMB 51.3-53.0 billion to RMB 58.5-60.5 billion, with revenue growth accelerated from 18%-22% to 35%-39%. Revenue, profit, and cash flow—all three lines were raised simultaneously.
When a bellwether company raises its annual guidance by over 10 percentage points in one go, it reflects not short-term volatility, but a clear judgment that downstream demand is strengthening.
II. What the Data Says
Start with BD deals. As of June 30, 2026, Chinese innovative drug out-licensing deals reached 81 transactions, with a total value of approximately $110 billion—already 80% of the full-year 2025 total. In July alone, 12 cross-border licensing deals were signed, totaling $9.253 billion. From January to July, total BD transaction value reached $106.3 billion, with Chinese companies claiming 8 of the global top 10 deals.
On August 4, Kangning Jerry announced a licensing agreement with U.S. AI drug developer Pathos AI, granting overseas rights to JSKN016, a first-in-class TROP2/HER3 bispecific ADC, with a total potential deal value exceeding $2.2 billion. This is the latest milestone in the accelerating出海 of Chinese innovative drugs.
Now look at corporate earnings. On August 5, BeiGene released its H1 2026 results—product revenue of $3.167 billion, up 31% year-over-year; adjusted net income of $820 million, up 111% year-over-year. Based on its H1 performance, BeiGene raised its full-year revenue guidance to $6.6-6.8 billion. RemeGen achieved profitability in the interim period. Innovent Biologics reported H1 product revenue exceeding RMB 8.2 billion, up over 55% year-over-year.
As of August 3, 104 pharmaceutical and biotech companies on the A-share market had disclosed H1 earnings forecasts, with 58 expecting net profit growth and 28 expecting growth of over 100% year-over-year. In the first half of 2026 alone, the NMPA approved 38 Class 1 innovative drugs, 11 of which were "global first" new drugs.
The CXO sector is validating the same trend. WuXi AppTec reported H1 revenue of RMB 28.9 billion, up 38.9% year-over-year, with net profit of RMB 11.08 billion. A China Securities research report on August 6 showed that global innovative drug financing in H1 2026 reached $20.177 billion, with domestic financing of $4.233 billion—already 82% of the full-year 2025 total. As capital gradually transmits from the financing side to CXO, upstream supply chains are becoming beneficiaries.
III. AI Is Moving from "Frontier Concept" to "Real R&D Infrastructure"
Another dimension of industry change comes from AI.
On August 3, J-Tech announced a partnership with Hengrui Medicine, with its proprietary AiTEM AI formulation innovation platform to be deployed locally at Hengrui to accelerate formulation development efficiency. This deal is not a conventional pipeline transaction—it is a capability procurement at the infrastructure level of AI-driven small-molecule formulation optimization.
J-Tech's NanoForge platform has accumulated over 10 million lipid structures and can shorten formulation optimization cycles to within three months. More importantly, this partnership sends a clear industry signal: AI is moving from a frontier technology that innovative drug companies are watching to a real R&D system being adopted by top-tier pharma.
IV. What These Changes Mean for Custom Synthesis
As the innovative drug industry shifts from "selling BD stories" to "clinical data + commercialization realization," upstream supply chain demand is undergoing structural changes.
More innovative drugs entering clinical and commercial stages translate into sustained demand for high-purity intermediates, chiral building blocks, and complex heterocyclic compounds. As a drug candidate moves from "target validation" to "clinical supply," and from "clinical" to "commercial preparation"—each stage places different demands on the supply chain: from gram-scale flexibility to kilogram-scale consistency; from rapid delivery to batch-to-batch reproducibility.
At the same time, AI is changing the efficiency curve of drug discovery. When AI makes it faster to "find molecules that might work," "turning molecules into testable compounds" still requires chemistry. The new targets and molecules identified by AI ultimately need to return to the lab—they require real compounds for validation.
V. Beixinke Chem's Perspective
As a custom synthesis service provider based in Shanghai, specializing in inhibitor small molecules, heterocyclic intermediates, and chiral building blocks, Beixinke Chem is witnessing the real-world transmission of this industry shift upstream.
From our front-line experience: since the beginning of 2026, we have seen a noticeable increase in inquiries for new product development. Compared to 2025, demand for custom synthesis from labs and research organizations is accelerating—with requirements that are more specific, more concrete, and more urgent.
Our core capabilities cover the entire chain from retrosynthetic analysis to process scale-up: chiral construction, heterocyclic assembly, milligram-to-kilogram scale-up, and full HPLC/LC-MS/NMR analytical support. We have provided custom synthesis support to R&D labs and biotech companies both in China and internationally—across different scales and requirements.
If your R&D team is also tracking what this industry shift means for your supply chain, we would welcome the conversation.